(Contributing to a statement from AstraZeneca)
By Carl O’Donnell
Feb 22 (Reuters) – Pfizer Inc expects to deliver more than 13 million doses of the COVID-19 vaccine to the United States by mid-March, more than doubling its shipments since early February, a senior said. Pfizer official in preparation for evidence ahead of Tuesday’s conference hearing.
Pfizer is on track to deliver 120 million doses of its two-dose regimen by the end of March, said John Young, Pfizer’s chief business officer.
Pfizer is also willing to give the United States a total of 300 million views by the end of July and has raised global production expectations for 2021 to at least 2 billion doses, he said.
In his own prepared remarks, Moderna Inc President Stephen Hoge said the drug dealer expects to deliver 100 million doses of his two-dose picture by the end of March, and 300 million by the end of July .
Johnson & Johnson estimates that it will be possible to send at least 20 million doses of the single-dose dose to the United States by the end of March after obtaining U.S. regulatory approval and 100 million doses by mid-2021. , Richard Nettles, Vice President of Medical Affairs.
The comments were prepared ahead of a U.S. conference hearing on access to vaccination to be held by the House Committee on Energy and Trade on Tuesday as the United States crossed the remarkable milestone of 500,000 COVID-19 deaths.
The comments set the United States on track to receive 240 million doses by the end of March, enough to absorb 130 million Americans, and 700 million doses by mid-year.
AstraZeneca Plc, which is running a U.S. test for the coronavirus vaccine, believes the bullet can adapt to new variants of the virus in its laboratory, said Ruud Dobber, president of the company, America North.
The infectious variant of COVID-19 has become common in South Africa and has appeared in several U.S. states. (Reporting by Carl O’Donnell in New York Edited by Rosalba O’Brien, Matthew Lewis and Ana Nicolaci da Costa)
Our Standards: The Principles of the Thomson Reuters Trust.